ROIV vs. ALNY, TEVA, GMAB, RPRX, BGNE, BMRN, VTRS, UTHR, SRPT, and RDY
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
Alnylam Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals presently has a consensus target price of $216.19, indicating a potential upside of 47.14%. Roivant Sciences has a consensus target price of $16.90, indicating a potential upside of 57.50%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Alnylam Pharmaceuticals.
Roivant Sciences has a net margin of 3,624.14% compared to Roivant Sciences' net margin of -16.58%. Roivant Sciences' return on equity of 0.00% beat Alnylam Pharmaceuticals' return on equity.
Alnylam Pharmaceuticals received 1048 more outperform votes than Roivant Sciences when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 75.00% of users gave Roivant Sciences an outperform vote.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Roivant Sciences had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 10 mentions for Roivant Sciences and 7 mentions for Alnylam Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.97 beat Alnylam Pharmaceuticals' score of 0.68 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.
Summary
Alnylam Pharmaceuticals and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
